Home » World » What is the Price of Corona Vaccine? This Explanation of the Ministry of BUMN

What is the Price of Corona Vaccine? This Explanation of the Ministry of BUMN

Jakarta, CNBC Indonesia – PT Bio Farma, the holding company of the state-owned insurance company (BUMN), is ready to produce 50 million Covid-19 vaccines for the first phase. The production capacity of this pharmaceutical company is considered sufficient to meet the needs of Indonesia.

This was stated by Special Staff of the Minister of SOEs Arya Sinulingga. He is optimistic that the procurement of Covid-19 vaccine for Indonesia will be realized soon. While the selling price will be set by the government.

“To meet our needs, Bio Farma is able to do that and can be done very quickly,” Arya said during an interview with CNBC Indonesia, Tuesday (07/21/2020).


Regarding the selling price of the corona vaccine to the public, Arya said, it would be determined by the government. But the price of the vaccine is estimated not far from the current price of the flu vaccine.

“For the price of vaccines, we know the price of the flu vaccine. Not much different from the price of the vaccine as well. I had a pneumonia vaccine yesterday, the price is much more expensive than this corona vaccine later. Standard really, that much too,” said Arya.

Bio Farma is an Indonesian pharmaceutical company that has world-recognized competence in producing vaccines. Even the World Health Organization (WHO) trusts Bio Farma to produce a number of vaccines.

As is known, Bio Farma, is ready to conduct phase 3 clinical trials for the Covid-19 vaccine. Bio Farma will use 2,400 Sinovac vaccines from China which arrived on July 19, 2020, for the initial phase of phase 3 clinical trials which will begin in August.

In a press release delivered by Bio Farma, Bio Farma’s Managing Director, Honesti Basyir said, clinical phase 3 of the Covid-19 vaccine was scheduled to run for six months, so it was targeted to be completed by January 2021.

“If the clinical trial of the Covid-19 vaccine phase 3 runs smoothly, Bio Farma will produce it in the upcoming Q1 2021, and we have prepared its production facilities at Bio Farma, with a maximum production capacity of 250 million doses,” Honesti said.

Honesti added, the reason for choosing Sinovac as a partner is the vaccine platform / vaccine manufacturing method used by Sinovac, the same as the competencies held by Bio Farma today. With the inactivation method, Bio Farma already has experience in making vaccines such as the Pertussis vaccine.

“The vaccine that arrived last Sunday, still needs a few more steps before clinical trials can be carried out in August 2020. The stages that must be passed include testing in the Bio Farma Laboratory, and several other permits,” Honesti said.

The development of the Covid-19 vaccine, is one of five Bio Farma scenarios, in dealing with the spread of the COV2 SARS virus that causes Covid-19, among others, the production of Real Time Polymerase Chain Reaction (RT-PCR), Convalent Plasma Therapy, Mobile Laboratory BSL 3, and Making Viral Transport Media (VTM).

Arya added, Sinovac is one of the companies that collaborates with Bio Farma. How many other pharmaceutical companies have collaborated with Bio Farma.

“Bio Farma already has international standards to be trusted by several countries. Even the WHO just asked Bio Farma to make (corona vaccine). WHO is currently also making vaccines and working with Bio Farma,” said Arya.

[Gambas:Video CNBC]

(HPS / HPS)


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.